Article Correctness Is Author's Responsibility: EBMT to track long-term outcome data for Kymriah®

(European Society for Blood and Marrow Transplantation) The European Society for Blood and Marrow Transplantation (EBMT) announces a new collaboration with Novartis Pharmaceuticals to study the long-term outcomes of patients treated with chimeric antigen receptor T cell (CAR T) therapies. Under the terms of the collaboration, EBMT will collect treatment and long-term safety and efficacy data from patients treated with Kymriah® (tisagenlecleucel) in both approved indications in the EBMT registry for cellular therapy in the European regions.